Saji T, Matsuura H, Hoshino K, Yamamoto S, Ishikita T, Matsuo N
Department of Pediatrics, Toho University, Tokyo, Japan.
Jpn Heart J. 1991 Sep;32(5):735-40. doi: 10.1536/ihj.32.735.
A small-for-gestational-age infant with cyanosis due to double outlet right ventricle with severe pulmonary stenosis and patent ductus arteriosus was treated with oral prostaglandin E1 derivative (OP-1206). The constricting ductus arteriosus dilated and the ductus-dependent pulmonary blood flow increased. The recommended dosage was 1.5-2.0 micrograms/kg/day which was lower than that of intravenous PGE1 or of oral PGE2. The administration interval was 6 hours, which was longer than that of oral PGE2. The patient was treated as an out-patient because continuous intravenous infusion was not necessary. Treatment was continued for 2 months without complication, at which time a Blalock-Taussig shunt operation was performed. Orally administered PGE1 derivative (OP-1206) was found to be equally effective to intravenous infusion of PGE1 for both short and long-term management of cyanotic heart disease in which the pulmonary blood flow is mostly dependent on the patency of the ductus arteriosus. Oral PGE1 derivative (OP-1206) may be a possible substitute for intravenous PGE1 infusion therapy.
一名因右心室双出口伴严重肺动脉狭窄及动脉导管未闭而出现紫绀的小于胎龄儿接受了口服前列腺素E1衍生物（OP - 1206）治疗。缩窄的动脉导管扩张，依赖动脉导管的肺血流量增加。推荐剂量为1.5 - 2.0微克/千克/天，低于静脉注射前列腺素E1或口服前列腺素E2的剂量。给药间隔为6小时，长于口服前列腺素E2的间隔时间。由于无需持续静脉输注，该患者作为门诊病人接受治疗。治疗持续了2个月无并发症发生，之后进行了布莱洛克 - 陶西格分流术。发现口服前列腺素E1衍生物（OP - 1206）在对肺血流量大多依赖动脉导管通畅的紫绀型心脏病的短期和长期治疗中，与静脉输注前列腺素E1同样有效。口服前列腺素E1衍生物（OP - 1206）可能是静脉输注前列腺素E1治疗的一种可行替代方法。
